Advanced Filters
noise
Found 2,256 clinical trials
P PI: Professor Carlo Palmieri

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Detection of molecular relapse with circulating tumour DNA analysis can identify which patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy. This trial will aim to demonstrate that palbociclib and fulvestrant, can defer or prevent relapse in patients with ctDNA detected molecular relapse. The TRAK-ER trial will …

18 years of age All Phase 2
T Tinh-Hai Collet, MD

Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)

This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of …

45 - 60 years of age Female Phase N/A
J Jean PALUSSIERE, MD

High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study

Monocentric prospective study evaluating the efficacy of High intensity focused ultrasound (HIFU) in breast tumors.

18 years of age Female Phase N/A
F Farah Zahran

SBRT for Breast Cancer Oligometastases

This is a prospective data collection of treatment outcome for newly diagnosed oligometastatic breast cancers with 1-3 bone metastases. Eligible patients will be identified from the weekly Breast MDC. Patients will receive the recommended systemic and local treatment (including metastases directed SBRT) according to our clinical practice guidelines.Patients will be …

18 years of age Female Phase N/A
D Demetra Christou, PhD

Rowing Following Breast Cancer Chemotherapy

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this …

40 - 80 years of age Female Phase N/A
S Simon Wernhart, MD

Exercise in Triple- Negative Breast Cancer

This is a prospective, randomized, controlled mono-center study investigating the effects of a combined, supervised aerobic exercise and resistance training in female patients with newly diagnosed, therapy-naive triple-negative breast cancer (TNBC, stage I-III) between 18 and 50 years of age scheduled for anthracycline-based chemotherapy and immunotherapy with checkpoint inhibitors. All …

18 - 65 years of age Female Phase N/A
J Juliana H Earwood, OTD, OTR/L

Cognitive Rehabilitation Following Breast Cancer Treatment

The goal of this proposed project is to evaluate the feasibility and preliminary effect of metacognitive strategy training to improve activity performance, cognition, and quality of life in breast cancer survivors with cancer-related cognitive impairment (CRCI). The other goal of this proposed project is to examine the effects of CO-OP …

20 - 75 years of age Female Phase N/A
W Wenjin Yin

Trastuzumab Deruxtecan in Advanced Breast Cancer

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

18 years of age All Phase N/A
A Andreia Soares, PhD

Mind Programme for Women With Breast Cancer

The Mind programme for cancer patients was developed by this project PI through the integration of ACT, mindfulness and CFT components specifically adapted to the needs of a cancer population. This intervention aims at improving well-being, preventing subsequent distress, and promoting adaptation to the disease and posttreatment period. A recent …

18 - 70 years of age Female Phase N/A
Z Zhonghua Wang, MD

Reverse HER2-negative Immune Resistant Breast Cancer

This is a Phase II, open-label study evaluating the efficacy and safety of combined treatment (retinoic acid) with immune checkpoint inhibitor in HER2-negative breast cancer patients who progressed during previous immune checkpoint inhibitors.

18 - 70 years of age Female Phase 2

Simplify language using AI